<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550977</url>
  </required_header>
  <id_info>
    <org_study_id>16119</org_study_id>
    <nct_id>NCT02550977</nct_id>
  </id_info>
  <brief_title>Russia/Ukraine Suppression of Ovarian Activity Study</brief_title>
  <official_title>Multicenter, Open-label, Uncontrolled Study to Investigate Suppression of Ovarian Activity of a Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in 80 Young Female Volunteers Over 3 Treatment Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look into the effectiveness of a new investigational
      medication applied as a transdermal patch. The patch is applied on the skin with study
      medication that is absorbed through the skin suppressing ovarian activity and therefore
      preventing an egg from leaving an ovary (ovulation). The study will look into the study
      drug`s safety and how well it is tolerated and its absorption, breakdown and elimination in
      the body. It describes how the body affects a specific drug after administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2015</start_date>
  <completion_date type="Actual">August 15, 2016</completion_date>
  <primary_completion_date type="Actual">July 15, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suppression of ovulatory activity proved by progesterone and estradiol concentrations</measure>
    <time_frame>Treatment day 29 to day 84</time_frame>
    <description>Estradiol levels &gt; 100pmol/L indicate some ovarian activity and progesterone levels &gt; 5nmol/L in subjects with estradiol levels &gt; 100pmol/L reflect ovulation or luteinized unruptured follicles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration, AUC (area under curve) of Gestodene</measure>
    <time_frame>Multiple time points up to treatment day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration, AUC (area under curve) of ethinyl estradiol</measure>
    <time_frame>Multiple time points up to treatment day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration, AUC (area under curve) of Sexual hormone binding globulin</measure>
    <time_frame>Multiple time points up to treatment day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal safety laboratory</measure>
    <time_frame>Up to 84 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of follicle-stimulating hormone</measure>
    <time_frame>Day 27 of pretreatment cycle to treatment day 83</time_frame>
    <description>Serum concentration of follicle-stimulating hormone (FSH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of luteinizing hormone</measure>
    <time_frame>Day 27 of pretreatment cycle to treatment day 83</time_frame>
    <description>Serum concentration of luteinizing hormone (LH)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Gestodene/EE Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gestodene/EE Patch (BAY86-5016)</intervention_name>
    <description>7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.</description>
    <arm_group_label>Gestodene/EE Patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects requesting contraception

          -  Aged 18 to 35 years (inclusive); smokers must not be older than 30 years

          -  Normal or clinically insignificant cervical smear not requiring further follow-up

          -  History of regular cyclic menstrual periods

          -  Willingness to use nonhormonal methods of contraception during the entire study

          -  Proven ovulation upon completion of the pretreatment cycle

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Obesity (body mass index [BMI] &gt; 30.0 kg/m2)

          -  Significant skin reaction to transdermal preparations or sensitivity to
             surgical/medical tape

          -  Any disease or condition that may worsen under hormonal treatment

          -  Use of hormonal contraception other than study medication during the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Irkutsk</city>
        <zip>664003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnodar</city>
        <zip>350063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>Transdermal contraceptive patch</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Gestodene</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

